Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 10, 2007
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-16686
|
58-1486040
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
180
Mt. Airy Road, Suite 102
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment
of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On
September 10, 2007, VioQuest Pharmaceuticals, Inc. (the “Company”), received an
email from Vincent M. Aita in which he resigned from the Board of Directors
of
the Company. In his notice of resignation, Dr. Aita indicated that his
responsibilities to his new employer would prevent him from performing his
role
adequately as Director and serving the best interests of the Company’s
shareholders.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VioQuest
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
Date:
September 14, 2007
|
By:
|
/s/
Brian Lenz
|
|
|
Brian
Lenz
|
|
|
Chief
Financial Officer
|